German inspectors find problems at Dr Reddy's' Duvvada plant

iStock/alexis84

German regulators have found problems as Dr Reddy’s’ drug formulations plant in Duvvada, Vishakapatnam.

Inspectors from Regierung von Oberbayern - the Bavarian regional Government – who audited the facility on September 7 made six “major observations” according to a statement issued to the Bombay Stock Exchange (BSE) last Friday.

Dr Reddy’s said it plans to submit a corrective and preventative action plan (CAPA) adding that “the auditor has cautioned that the facility will receive EU-GMP certification from the regulator upto November 2018 only when the regulator approves the CAPA.”

The firm also said that no pharmaceutical products made at Duvvada plant are currently exported to European Union (EU) member states.

The news comes just a month after inspectors from the same German agency refused to renew the good manufacturing practice (GMP) certificate for Dr Reddy’s plant in Bachupally, Hyderabad.

The Duvvada facility – which formulates cancer drugs – has also been criticized by the US Food and Drug Administration (FDA) on several occasions.

In 2015, the agency issued Dr Reddy’s with a warning letter about operations at the site.

And FDA auditors who visited to re-inspect the facility in March this year issued the firm with a Form 483 detailing 13 observations.

Related News

Image: iStock/Golden_Brown

Re-inspection lands Dr Reddy’s Form 483 with 13 observations at Duvvada plant

iStock/Vepar5

Dr Reddy's says US FDA has issued Form 483 for Srikakulam API plant

iStock/daboost

Dr Reddy's says US FDA has closed Miryalaguda plant audit

iStock/alexis84

Germany refuses to renew GMP cert for Dr Reddy's Bachupally FTO 2 plant

iStock/ajijchan

Dr Reddy's: No production halt at Bachupally plant hit with Form 483

Dr Reddy's revealed the Warning Letter on Friday

Three Dr Reddy’s sites hit with Warning Letters in India

AstraZeneca objects to Dr Reddy's using the same colour in its pills as Nexium (pictured. CC: Rennett Stowe)

AZ halts Dr Reddy’s ‘purple pill’ generic; firm responds to FDA Letter

Dr Reddy's saw API revenues slide in FY Q1 2018

Dr Reddy's saw API revenues slide in FY Q1 2018

Related Products

See more related products